While Orexigen (OREX +68%) has reason to feel good about restarting development of its rejected...

|About: Orexigen Therapeutics, ... (OREX)|By:, SA News Editor

While Orexigen (OREX +68%) has reason to feel good about restarting development of its rejected obesity drug Contrave, the path to approval remains pockmarked with risk and expense. With the FDA asking for an almost unprecedented 10K-patient safety study, Adam Feurstein says 2015-2016 (vs. OREX's 2014) is a more realistic timeline.